bacterial flavoproteins Inhibitors
2 drugsAbout bacterial flavoproteins
Bacterial flavoproteins are enzymes using flavin cofactors (FAD or FMN) to catalyze redox reactions essential for bacterial metabolism. They are attractive drug targets due to their critical roles in bacterial processes, potentially allowing selective inhibition.
Bacterial flavoproteins are therapeutically relevant, though no genetic evidence directly links them to disease pathogenesis. The success of drugs targeting these enzymes underscores their importance as antibacterial targets.
Bacterial flavoproteins are targeted by two FDA-approved small molecule drugs: MACRODANTIN and MACROBID. These drugs, marketed by ALMATICA, are used to treat other indications.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Uncomplicated Urinary Tract Infections with only 1 trials.
Top bacterial flavoproteins Drugs
ALMATICA is the only company with approved drugs targeting bacterial flavoproteins.
Low competition may indicate high entry barriers or limited market potential for new entrants.
bacterial flavoproteins Drug Modality Landscape
Modalities
Routes of Administration
bacterial flavoproteins is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or peptides could offer differentiation in this space.
bacterial flavoproteins Clinical Trials 33 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 3 | 1 | 0 | 1 | 100% |
| Phase 2 | 1 | 1 | 0 | 0 | 100% |
| Phase 3 | 6 | 3 | 1 | 2 | 75% |
| Phase 4 | 23 | 13 | 2 | 8 | 87% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
bacterial flavoproteins Drug Approval Timeline (1970 - 1991)
The first drug was approved in 1970, and the most recent in 1991, spanning 22 years.
The long gap since the last approval suggests a potential saturation or a need for innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 38 clinical trials targeting bacterial flavoproteins.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities